Track Formycon AG — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Formycon AG FYB.DE · Stock Open Formycon AG in new tab

19.06 EUR
EPS
-1.42
P/B
0.87
ROE
-6.33
Beta
0.70
Target Price
39.67 EUR
Loading chart...
Key Metrics
Earnings dateApril 29, 2027
EPS-1.42
Book Value21.82
Price to Book0.87
Debt/Equity2.21
% Insiders30.413%
Growth
Revenue Growth2.43%
Estimates
Forward P/E16.92
Forward EPS1.12
Target Mean Price39.67

DCF valuation

Model fair value for Formycon AG (FYB.DE)
Result
Sign in to run the valuation for FYB.DE.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 39.67 EUR (low 30.00, high 51.00)
Low 30.00
Mean 39.67
High 51.00
Price 19.06
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Formycon AG Logo Formycon AG Analysis (FYB.DE)

Germany Health Care Official Website Stock

Is Formycon AG a good investment? Formycon AG (FYB.DE) is currently trading at 19.06 EUR. Market analysts have a consensus price target of 39.67 EUR. This suggests a potential upside from current levels.

Earnings Schedule: Formycon AG is expected to release its next earnings report on April 29, 2027. The market consensus estimate for Forward EPS is 1.12.

Investor FAQ

Does Formycon AG pay a dividend?

No, it does not currently pay a dividend.

What asset class is Formycon AG?

Formycon AG is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be April 29, 2027. The company currently has a trailing EPS of -1.42.

Company Profile

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well as AHZANTIVE, Baiama, and Fovlya brand names. The company's pipeline includes ustekinumab used in the treatment of Crohn's disease, ulcerative colitis, Plaque Psoriasis, and Psoriatic Arthritis under the Otulf, Fymskina, and Sitovab brand names. It is also developing pembrolizumab for the treatment of immuno-oncology diseases, such as advanced melanoma, non-small cell bronchial carcinoma, asthma, hodgkin's lymphoma, urothelial carcinomas, tumors in the head and neck area, sinusitis with nasal polyps area, other tumor and genetic diseases; and FYB208 and FYB209 that is indicated for immunology areas. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Exchange Ticker
GER (Germany) FYB.DE
FRA (Germany) FYB.F
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion